Switzerland · Delayed Price · Currency is CHF Tecan Group AG Earnings Call Transcripts
Fiscal Year 2026
-
A new CEO is driving a transformation program focused on portfolio discipline, commercial and operational excellence to reignite growth. Automation and AI are key market drivers, with new products and geographic expansion supporting a gradual recovery and midterm growth targets.
Fiscal Year 2025
-
2025 saw a slight sales decline and a net loss due to impairment, but strong cash flow and a robust order book support a stable dividend. The Rewire program targets CHF 1 billion sales and 20% EBITDA by 2028, with gradual market recovery and operational improvements expected.
-
Revenue and adjusted EBITDA for H1 2025 met expectations amid challenging markets, with strong clinical diagnostics and improved gross margin offsetting declines in China and Partnering. Full-year guidance is maintained, with tariff and FX risks mitigated by cost controls and operational flexibility.
-
The conference highlighted a resilient, innovation-driven strategy focused on automation, digital solutions, and high-growth applications in genomics and proteomics. Despite a challenging 2024, with revenue declines in China and biopharma, the company reaffirmed its midterm growth and margin outlook, supported by ongoing M&A and sustainability initiatives.
Fiscal Year 2024
-
2024 saw double-digit sales and profit declines due to weak biopharma, US government, and China demand, but recurring revenues and clinical diagnostics offset some headwinds. 2025 guidance anticipates flat to slightly positive sales, with margin improvement from cost savings and new product launches.
-
Facing a challenging 2024 with revised guidance due to OEM demand deferrals and China softness, the company is implementing cost controls and focusing on high-growth segments, digital innovation, and global expansion. Mid-term, it targets a return to above-market growth and margin improvement, supported by strong recurring revenue and new product launches like Veya.
-
Sales declined 11.6% in local currencies in H1 2024, mainly due to biopharma and China weakness, with adjusted EBITDA margin at 14.5%. Guidance for 2024 was revised downward, but order intake improved in Q2 and new product launches are expected to drive growth in 2025.